Advertisement
Screener

HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) Overview

HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 1.28; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 0.55; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.87; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.68; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$25.21$28.31$31.79$35.69$40.08$45.002025-11-062026-11-06$18.24$23.44$30.13$38.72$49.76$63.962021-11-082026-11-06$18.24$23.44$30.13$38.72$49.76$63.962020-08-192026-11-06$18.24$23.44$30.13$38.72$49.76$63.962020-08-192026-11-06$18.24$23.44$30.13$38.72$49.76$63.962020-08-192026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$33.11
Previous close
$39.29
Change
-$6.18
Change (%)
-15.73%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

HRMY
+5.00%
S&P 500
(m)

1 year

HRMY
+42.15%
S&P 500
(m)

3 years

HRMY
+19.90%
S&P 500
(m)

5 years

HRMY
+5.03%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 1.28

0.470.720.971.211.4631 Mar 2025: estimate (m); actual 0.7831 Mar 2025(m)30 Jun 2025: estimate (m); actual 0.6830 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.8730 Sept 2025(m)31 Mar 2026: estimate (m); actual 0.5531 Mar 2026(m)30 Jun 2026: estimate (m); actual 1.2830 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)1.28(m)(m)
1 Jan 202631 Mar 2026(m)0.55(m)(m)
1 Jul 202530 Sept 2025(m)0.87(m)(m)
1 Apr 202530 Jun 2025(m)0.68(m)(m)
1 Jan 202531 Mar 2025(m)0.78(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 2.71

0.501.161.832.493.1531 Dec 2021: estimate (m); actual 0.5831 Dec 2021(m)31 Dec 2022: estimate (m); actual 2.9731 Dec 2022(m)31 Dec 2023: estimate (m); actual 2.1331 Dec 2023(m)31 Dec 2024: estimate (m); actual 2.5131 Dec 2024(m)31 Dec 2025: estimate (m); actual 2.7131 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)2.71(m)(m)
1 Jan 202431 Dec 2024(m)2.51(m)(m)
1 Jan 202331 Dec 2023(m)2.13(m)(m)
1 Jan 202231 Dec 2022(m)2.97(m)(m)
1 Jan 202131 Dec 2021(m)0.58(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 261.28M ■ Earnings 75.43M — Profit margin 28.87%

-31.35M8.2%76.64M15.4%184.64M22.7%292.63M29.9%30 Sept 2025: revenue 239.46M; earnings 50.87M; profit margin 21.24%30 Sept 202531 Dec 2025: revenue 243.78M*; earnings 22.49M*; profit margin 9.22%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 215.39M; earnings 32.49M; profit margin 15.08%31 Mar 202630 Jun 2026: revenue 261.28M; earnings 75.43M; profit margin 28.87%30 Jun 2026

31 Dec 2025 ■ Revenue 868.45M ■ Earnings 158.69M — Profit margin 18.27%

-104.21M17.3%254.75M25.7%613.71M34.1%972.67M42.4%31 Dec 2022: revenue 437.86M; earnings 181.47M; profit margin 41.44%31 Dec 202231 Dec 2023: revenue 582.02M; earnings 128.85M; profit margin 22.14%31 Dec 202331 Dec 2024: revenue 714.73M; earnings 145.49M; profit margin 20.36%31 Dec 202431 Dec 2025: revenue 868.45M; earnings 158.69M; profit margin 18.27%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$33.11(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$33.11High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning HRMY

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$181.27M
Profit margin
18.88%
Return on assets · 12 month
14.61%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
293.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.13M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-5.39%*
Total return · month
0.20%*
Total return · quarter
11.18%*
Total return · half year
48.04%*
Total return · year to date
5.00%*
Total return · 1 year
42.15%*
Total return · 3 years
19.90%*
Total return · 5 years
5.03%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$959.90M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
15.41%*
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

HARMONY BIOSCIENCES HOLDINGS, INC. Overview

View more →

(m)

(m)

SEC CIK
1802665
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
630 W GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING, Pennsylvania, 19462, United States
Fiscal year end
1231
Phone
(484) 539-9800

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
uniQure N.V. (QURE)$2.416B-4.93
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Immunome Inc. (IMNM)United States$2.538B-9.45
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Zai Lab Ltd (ZLAB)$2.241B-113.34